[en] BACKGROUND/AIMS: In this multicentre study in clinical settings, we assessed the accuracy of optimized procedures for FDG-PET brain metabolism and CSF classifications in predicting or excluding the conversion to Alzheimer's disease (AD) dementia and non-AD dementias. METHODS: We included 80 MCI subjects with neurological and neuropsychological assessments, FDG-PET scan and CSF measures at entry, all with clinical follow-up. FDG-PET data were analysed with a validated voxel-based SPM method. Resulting single-subject SPM maps were classified by five imaging experts according to the disease-specific patterns, as "typical-AD", "atypical-AD" (i.e. posterior cortical atrophy, asymmetric logopenic AD variant, frontal-AD variant), "non-AD" (i.e. behavioural variant FTD, corticobasal degeneration, semantic variant FTD; dementia with Lewy bodies) or "negative" patterns. To perform the statistical analyses, the individual patterns were grouped either as "AD dementia vs. non-AD dementia (all diseases)" or as "FTD vs. non-FTD (all diseases)". Aβ42, total and phosphorylated Tau CSF-levels were classified dichotomously, and using the Erlangen Score algorithm. Multivariate logistic models tested the prognostic accuracy of FDG-PET-SPM and CSF dichotomous classifications. Accuracy of Erlangen score and Erlangen Score aided by FDG-PET SPM classification was evaluated. RESULTS: The multivariate logistic model identified FDG-PET "AD" SPM classification (Expβ = 19.35, 95% C.I. 4.8-77.8, p < 0.001) and CSF Aβ42 (Expβ = 6.5, 95% C.I. 1.64-25.43, p < 0.05) as the best predictors of conversion from MCI to AD dementia. The "FTD" SPM pattern significantly predicted conversion to FTD dementias at follow-up (Expβ = 14, 95% C.I. 3.1-63, p < 0.001). Overall, FDG-PET-SPM classification was the most accurate biomarker, able to correctly differentiate either the MCI subjects who converted to AD or FTD dementias, and those who remained stable or reverted to normal cognition (Expβ = 17.9, 95% C.I. 4.55-70.46, p < 0.001). CONCLUSIONS: Our results support the relevant role of FDG-PET-SPM classification in predicting progression to different dementia conditions in prodromal MCI phase, and in the exclusion of progression, outperforming CSF biomarkers.
Albert, M.S., DeKosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., Gamst, A., Holtzman, D.M., Jagust, W.J., Petersen, R.C., Snyder, P.J., Carrillo, M.C., Theis, B., Phelps, C.H., The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on. Alzheimers Dement. 7 (2011), 270–279, 10.1016/j.jalz.2011.03.008.The.
Anchisi, D., Borroni, B., Franceschi, M., Kerrouche, N., Kalbe, E., Beuthien-Beumann, B., Cappa, S., Lenz, O., Ludecke, S., Marcone, A., Mielke, R., Ortelli, P., Padovani, A., Pelati, O., Pupi, A., Scarpini, E., Weisenbach, S., Herholz, K., Salmon, E., Holthoff, V., Sorbi, S., Fazio, F., Perani, D., Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch. Neurol. 62 (2005), 1728–1733, 10.1001/archneur.62.11.1728.
Arbizu, J., Prieto, E., Martínez-Lage, P., Martí-Climent, J.M., García-Granero, M., Lamet, I., Pastor, P., Riverol, M., Gómez-Isla, M.T., Peñuelas, I., Richter, J.A., Weiner, M.W., Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia. Eur. J. Nucl. Med. Mol. Imaging 40 (2013), 1394–1405, 10.1007/s00259-013-2458-z.
Armstrong, M.J., Litvan, I., Lang, A.E., Bak, T.H., Bhatia, K.P., Borroni, B., Boxer, A.L., Dickson, D.W., Grossman, M., Hallett, M., Josephs, K.A., Kertesz, A., Lee, S.E., Miller, B.L., Reich, S.G., Riley, D.E., Tolosa, E., Tröster, A.I., Vidailhet, M., Weiner, W.J., Criteria for the diagnosis of corticobasal degeneration. Neurology 80 (2013), 496–503, 10.1212/WNL.0b013e31827f0fd1.
Bateman, R.J., Xiong, C., Benzinger, T.L.S., Fagan, A.M., Goate, A., Fox, N.C., Marcus, D.S., Cairns, N.J., Xie, X., Blazey, T.M., Holtzman, D.M., Santacruz, A., Buckles, V., Oliver, A., Moulder, K., Aisen, P.S., Ghetti, B., Klunk, W.E., McDade, E., Martins, R.N., Masters, C.L., Mayeux, R., Ringman, J.M., Rossor, M.N., Schofield, P.R., Sperling, R.A., Salloway, S., Morris, J.C., Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367 (2012), 795–804, 10.1056/NEJMoa1202753.
Bittner, T., Zetterberg, H., Teunissen, C.E., Ostlund, R.E., Militello, M., Andreasson, U., Hubeek, I., Gibson, D., Chu, D.C., Eichenlaub, U., Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid. Alzheimers Dement. 12 (2016), 517–526.
Blennow, K., Johansson, A., Zetterberg, H., Diagnostic value of 14-3-3beta immunoblot and T-tau/P-tau ratio in clinically suspected Creutzfeldt-Jakob disease. Int. J. Mol. Med. 16 (2005), 1147–1149.
Blennow, K., Dubois, B., Fagan, A.M., Lewczuk, P., De Leon, M.J., Hampel, H., Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement. 11 (2015), 58–69, 10.1016/j.jalz.2014.02.004.
Bloudek, L.M., Spackman, D.E., Blankenburg, M., Sullivan, S.D., Review and Meta-analysis of Biomarkers and Diagnostic Imaging in Alzheimer's Disease. 26, 2011, 1–5.
Bohnen, N.I., Djang, D.S.W., Herholz, K., Anzai, Y., Minoshima, S., Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature. J. Nucl. Med. 53 (2012), 59–71, 10.2967/jnumed.111.096578.
Caminiti, S.P., Alongi, P., Majno, L., Volontè, M.A., Cerami, C., Gianolli, L., Comi, G., Perani, D., Evaluation of an optimized [18F]fluoro-deoxy-glucose positron emission tomography voxel-wise method to early support differential diagnosis in atypical Parkinsonian disorders. Eur. J. Neurol. 24 (2017), 1–8, 10.1111/ene.13269.
Caroli, A., Prestia, A., Chen, K., Ayutyanont, N., Landau, S.M., Madison, C.M., Haense, C., Herholz, K., Nobili, F., Reiman, E.M., Jagust, W.J., Frisoni, G.B., Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. J. Nucl. Med. 53 (2012), 592–600, 10.2967/jnumed.111.094946.
Cerami, C., Della Rosa, P.A., Magnani, G., Santangelo, R., Marcone, A., Cappa, S.F., Perani, D., Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia. NeuroImage Clin. 7 (2015), 187–194, 10.1016/j.nicl.2014.12.004.
Cerami, C., Dodich, A., Lettieri, G., Iannaccone, S., Magnani, G., Marcone, A., Gianolli, L., Cappa, S.F., Perani, D., Different FDG-PET metabolic patterns at single-subject level in the behavioral variant of fronto-temporal dementia. Cortex 83 (2016), 101–112, 10.1016/j.cortex.2016.07.008.
Cerami, C., Dodich, A., Greco, L., Iannaccone, S., Magnani, G., Marcone, A., Pelagallo, E., Santangelo, R., Cappa, S.F., Perani, D., The role of single-subject brain metabolic patterns in the early differential diagnosis of primary progressive aphasias and in prediction of progression to dementia. J. Alzheimers Dis. 55 (2017), 183–197.
Chen, X., Zhou, Y., Wang, R., Cao, H., Reid, S., Gao, R., Han, D., Initiative, A.D.N., Potential clinical value of multiparametric PET in the prediction of Alzheimer's disease progression. PLoS One, 11, 2016, e0154406.
Chételat, G., Desgranges, B., de la Sayette, V., Viader, F., Eustache, F., Baron, J.-C., Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology 60 (2003), 1374–1377.
Chételat, G., Desgranges, B., Landeau, B., Mézenge, F., Poline, J.B., de la Sayette, V., Viader, F., Eustache, F., Baron, J.-C., Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain 131 (2008), 60–71, 10.1093/brain/awm288.
Chiba, Y., Iseki, E., Fujishiro, H., Ota, K., Kasanuki, K., Hirayasu, Y., Arai, H., Sato, K., Early differential diagnostic between Alzheimer's disease and dementia with Lewy bodies: Comparison between FDG-PET and IMP-SPECT. Alzheimers Dement. 9 (2013), P374–P375.
Choo, I.H., Ni, R., Schöll, M., Wall, A., Almkvist, O., Nordberg, A., Combination of (18)F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients. J. Alzheimers Dis. 33 (2013), 929–939, 10.3233/JAD-2012-121489.
Della Rosa, P.A., Cerami, C., Gallivanone, F., Prestia, A., Caroli, A., Castiglioni, I., Gilardi, M.C., Frisoni, G., Friston, K., Ashburner, J., A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics 12 (2014), 575–593.
DeLong, E.R., DeLong, D.M., Clarke-Pearson, D.L., Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics, 1988, 837–845.
Drzezga, A., Grimmer, T., Henriksen, G., Stangier, I., Perneczky, R., Diehl-Schmid, J., Mathis, C.A., Klunk, W.E., Price, J., DeKosky, S., Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. NeuroImage 39 (2008), 619–633.
Dubois, B., Feldman, H., Jacova, C., Dekosky, S., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., Meguro, K., O'brien, J., Pasquier, F., Robert, P., Rossor, M., Salloway, S., Stern, Y., Visser, P., Scheltens, P., Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet 6 (2007), 734–746.
Dubois, B., Feldman, H.H., Jacova, C., Hampel, H., Molinuevo, J.L., Blennow, K., Dekosky, S.T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G.B., Fox, N.C., Galasko, D., Habert, M., Jicha, G.A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., De Souza, L.C., Vellas, B., Visser, P.J., Schneider, L., Stern, Y., Scheltens, P., Cummings, J.L., Curie-paris, P.M., De, H., Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 13 (2014), 614–629, 10.1016/S1474-4422(14)70090-0.
Dukart, J., Sambataro, F., Bertolino, A., Accurate prediction of conversion to Alzheimer's disease using imaging, genetic, and neuropsychological biomarkers. J. Alzheimers Dis. 49 (2015), 1143–1159, 10.3233/JAD-150570.
Ewers, M., Mattsson, N., Minthon, L., Molinuevo, J.L., Antonell, A., Popp, J., Jessen, F., Herukka, S.-K., Soininen, H., Maetzler, W., CSF biomarkers for the differential diagnosis of Alzheimer's disease: a large-scale international multicenter study. Alzheimers Dement. 11 (2015), 1306–1315.
Fellgiebel, A., Scheurich, A., Bartenstein, P., Müller, M.J., FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Res. Neuroimaging 155 (2007), 167–171, 10.1016/j.pscychresns.2006.12.002.
Fischer, P., Jungwirth, S., Zehetmayer, S., Weissgram, S., Hoenigschnabl, S., Gelpi, E., Krampla, W., Tragl, K.H., Conversion From Subtypes of Mild Cognitive Impairment to Alzheimer Dementia. 2007.
Frisoni, G.B., Bocchetta, M., Chételat, G., Rabinovici, G.D., de Leon, M.J., Kaye, J., Reiman, E.M., Scheltens, P., Barkhof, F., Black, S.E., Brooks, D.J., Carrillo, M.C., Fox, N.C., Herholz, K., Nordberg, A., Jack, C.R., Jagust, W.J., Johnson, K.A., Rowe, C.C., Sperling, R.A., Thies, W., Wahlund, L.-O., Weiner, M.W., Pasqualetti, P., Decarli, C., Imaging markers for Alzheimer disease: which vs how. Neurology 81 (2013), 487–500, 10.1212/WNL.0b013e31829d86e8.
Frisoni, G.B., Perani, D., Bastianello, S., Bernardi, G., Porteri, C., Boccardi, M., Cappa, S.F., Trabucchi, M., Padovani, A., Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap. Neurobiol. Aging 52 (2017), 119–131, 10.1016/j.neurobiolaging.2016.02.033.
Friston, K.J., Holmes, A.P., Worsley, K.J., Poline, J., Frith, C.D., Frackowiak, R.S.J., Statistical parametric maps in functional imaging: a general linear approach. Hum. Brain Mapp. 2 (1994), 189–210.
Fujishiro, H., Iseki, E., Kasanuki, K., Chiba, Y., Ota, K., Murayama, N., Sato, K., A follow up study of non-demented patients with primary visual cortical hypometabolism: prodromal dementia with Lewy bodies. J. Neurol. Sci. 334 (2013), 48–54.
Galluzzi, S., Geroldi, C., Amicucci, G., Bocchio-Chiavetto, L., Bonetti, M., Bonvicini, C., Cotelli, M., Ghidoni, R., Paghera, B., Zanetti, O., Frisoni, G.B., Archetti, S., Benussi, L., Binetti, G., Canu, E., Caobelli, F., Cavedo, E., Chitò, E., Costardi, D., Gennarelli, M., Giubbini, R., Guerra, U.P., Kuffenschin, G., Lussignoli, G., Moretti, D., Orlandini, A., Parapini, M., Paternicò, D., Porteri, C., Romano, M., Rosini, S., Scarpazza, C., Villa, I., Zanardini, R., Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. J. Neurol. 260 (2013), 640–650, 10.1007/s00415-012-6694-0.
Garibotto, V., Herholz, K., Boccardi, M., Picco, A., Varrone, A., Nordberg, A., Nobili, F., Ratib, O., for the Roadmap, G.T.F, Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol. Aging 52 (2017), 183–195.
Gaugler, J.E., Kane, R.L., Johnston, J.A., Sarsour, K., Sensitivity and specificity of diagnostic accuracy in Alzheimer's disease: a synthesis of existing evidence. Am. J. Alzheimers Dis. Other Demen. 28 (2013), 337–347, 10.1177/1533317513488910.
Gomar, J.J., Conejero-Goldberg, C., Davies, P., Goldberg, T.E., Initiative, A.D.N., Extension and refinement of the predictive value of different classes of markers in ADNI: four-year follow-up data. Alzheimers Dement. 10 (2014), 704–712.
Gorno-Tempini, M.L., Hillis, A.E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S.F., Ogar, J.M., Rohrer, J.D., Black, S., Boeve, B.F., Manes, F., Dronkers, N.F., Vandenberghe, R., Rascovsky, K., Patterson, K., Miller, B.L., Knopman, D.S., Hodges, J.R., Mesulam, M.M., Grossman, M., Classification of primary progressive aphasia and its variants. Neurology 76 (2011), 1006–1014, 10.1212/WNL.0b013e31821103e6.
Guerra, U.P., Nobili, F.M., Padovani, A., Perani, D., Pupi, A., Sorbi, S., Trabucchi, M., Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice. Neurol. Sci. 36 (2015), 1075–1081, 10.1007/s10072-015-2079-3.
van Harten, A.C., Kester, M.I., Visser, P.-J., Blankenstein, M.A., Pijnenburg, Y.A.L., van der Flier, W.M., Scheltens, P., Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin. Chem. Lab. Med. 49 (2011), 353–366.
Heiss, W.-D., Herholz, K., Böcher-Schwarz, H.G., Pawlik, G., Wienhard, K., Steinbrich, W., Friedmann, G., PET, CT, and MR imaging in cerebrovascular disease. J. Comput. Assist. Tomogr. 10 (1986), 903–911.
Hinrichs, C., Singh, V., Xu, G., Johnson, S.C., Predictive markers for AD in a multi-modality framework: an analysis of MCI progression in the ADNI population. NeuroImage 55 (2011), 574–589, 10.1016/j.neuroimage.2010.10.081.
Hughes, C.P., Berg, L., Danziger, W.L., Coben, L.A., Martin, R., A new clinical scale for the staging of dementia. Br. J. Psychiatry 140 (1982), 566–572.
Iaccarino, L., Crespi, C., Della Rosa, P.A., Catricalà, E., Guidi, L., Marcone, A., Tagliavini, F., Magnani, G., Cappa, S.F., Perani, D., The semantic variant of primary progressive aphasia: clinical and neuroimaging evidence in single subjects. PLoS One, 10, 2015, e0120197, 10.1371/journal.pone.0120197.
Iaccarino, L., Chiotis, K., Alongi, P., Almkvist, O., Wall, A., Cerami, C., Bettinardi, V., Gianolli, L., Nordberg, A., Perani, D., A cross-validation of FDG- and amyloid-PET biomarkers in mild cognitive impairment for the risk prediction to dementia due to Alzheimer's disease in a clinical setting. J. Alzheimers Dis., 2017, 1–12, 10.3233/JAD-170158.
Jansen, W.J., Ossenkoppele, R., Knol, D.L., Tijms, B.M., Scheltens, P., Verhey, F.R.J., Visser, P.J., Aalten, P., Aarsland, D., Alcolea, D., Alexander, M., Almdahl, I.S., Arnold, S.E., Baldeiras, I., Barthel, H., van Berckel, B.N.M., Bibeau, K., Blennow, K., Brooks, D.J., van Buchem, M.A., Camus, V., Cavedo, E., Chen, K., Chetelat, G., Cohen, A.D., Drzezga, A., Engelborghs, S., Fagan, A.M., Fladby, T., Fleisher, A.S., van der Flier, W.M., Ford, L., Förster, S., Fortea, J., Foskett, N., Frederiksen, K.S., Freund-Levi, Y., Frisoni, G.B., Froelich, L., Gabryelewicz, T., Gill, K.D., Gkatzima, O., Gómez-Tortosa, E., Gordon, M.F., Grimmer, T., Hampel, H., Hausner, L., Hellwig, S., Herukka, S.-K., Hildebrandt, H., Ishihara, L., Ivanoiu, A., Jagust, W.J., Johannsen, P., Kandimalla, R., Kapaki, E., Klimkowicz-Mrowiec, A., Klunk, W.E., Köhler, S., Koglin, N., Kornhuber, J., Kramberger, M.G., Van Laere, K., Landau, S.M., Lee, D.Y., de Leon, M., Lisetti, V., Lleó, A., Madsen, K., Maier, W., Marcusson, J., Mattsson, N., de Mendonça, A., Meulenbroek, O., Meyer, P.T., Mintun, M.A., Mok, V., Molinuevo, J.L., Møllergård, H.M., Morris, J.C., Mroczko, B., Van der Mussele, S., Na, D.L., Newberg, A., Nordberg, A., Nordlund, A., Novak, G.P., Paraskevas, G.P., Parnetti, L., Perera, G., Peters, O., Popp, J., Prabhakar, S., Rabinovici, G.D., Ramakers, I.H.G.B., Rami, L., Resende de Oliveira, C., Rinne, J.O., Rodrigue, K.M., Rodríguez-Rodríguez, E., Roe, C.M., Rot, U., Rowe, C.C., Rüther, E., Sabri, O., Sanchez-Juan, P., Santana, I., Sarazin, M., Schröder, J., Schütte, C., Seo, S.W., Soetewey, F., Soininen, H., Spiru, L., Struyfs, H., Teunissen, C.E., Tsolaki, M., Vandenberghe, R., Verbeek, M.M., Villemagne, V.L., Vos, S.J.B., van Waalwijk van Doorn, L.J.C., Waldemar, G., Wallin, A., Wallin, Å.K., Wiltfang, J., Wolk, D.A., Zboch, M., Zetterberg, H., Prevalence of cerebral amyloid pathology in persons without dementia. JAMA, 313, 2015, 1924, 10.1001/jama.2015.4668.
Kaerst, L., Kuhlmann, A., Wedekind, D., Stoeck, K., Lange, P., Zerr, I., Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease. J. Alzheimers Dis. 38 (2014), 63–73, 10.3233/JAD-130995.
Kalpouzos, G., Eustache, F., de la Sayette, V., Viader, F., Chételat, G., Desgranges, B., Working memory and FDG–PET dissociate early and late onset Alzheimer disease patients. J. Neurol. 252 (2005), 548–558.
Kato, T., Inui, Y., Nakamura, A., Ito, K., Brain fluorodeoxyglucose (FDG) PET in dementia. Ageing Res. Rev. 30 (2016), 73–84, 10.1016/j.arr.2016.02.003.
Landau, S.M., Harvey, D., Madison, C.M., Reiman, E.M., Foster, N.L., Aisen, P.S., Petersen, R.C., Shaw, L.M., Trojanowski, J.Q., Jack, C.R., Weiner, M.W., Jagust, W.J., Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75 (2010), 230–238, 10.1212/WNL.0b013e3181e8e8b8.
Lewczuk, P., Zimmermann, R., Wiltfang, J., Kornhuber, J., Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers. J. Neural Transm. 116 (2009), 1163–1167, 10.1007/s00702-009-0277-y.
Lewczuk, P., Kornhuber, J., Toledo, J.B., Trojanowski, J.Q., Knapik-Czajka, M., Peters, O., Wiltfang, J., Shaw, L.M., Validation of the erlangen score algorithm for the prediction of the development of dementia due to Alzheimer's disease in pre-dementia subjects. J. Alzheimers Dis. 48 (2015), 433–441, 10.3233/JAD-150342.
Litvan, I., Mangone, C.A., McKee, A., Verny, M., Parsa, A., Jellinger, K., D'Olhaberriague, L., Chaudhuri, K.R., Pearce, R.K., Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J. Neurol. Neurosurg. Psychiatry 60 (1996), 615–620.
Löppönen, M., Räihä, I., Isoaho, R., Vahlberg, T., Kivelä, S.-L., Diagnosing cognitive impairment and dementia in primary health care–a more active approach is needed. Age Ageing 32 (2003), 606–612.
Mattsson, N., Zetterberg, H., Lessons from multicenter studies on CSF biomarkers for Alzheimer's disease. Int. J. Alzheimers Dis., 2010, 2010.
Mattsson, N., Lönneborg, A., Boccardi, M., Blennow, K., Hansson, O., for the Roadmap, G.T.F, Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol. Aging 52 (2017), 196–213.
McKeith, I.G., Boeve, B.F., Dickson, D.W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C.G., Diagnosis and management of dementia with Lewy bodies Fourth consensus report of the DLB Consortium. Neurology, 2017, 10–1212.
McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R., Kawas, C.H., Klunk, W.E., Koroshetz, W.J., Manly, J.J., Mayeux, R., Mohs, R.C., Morris, J.C., Rossor, M.N., Scheltens, P., Carrillo, M.C., Thies, B., Weintraub, S., Phelps, C.H., The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7 (2011), 263–269, 10.1016/j.jalz.2011.03.005.
McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R. Jr., Kawas, C.H., Klunk, W.E., Koroshetz, W.J., Manly, J.J., Mayeux, R., The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7 (2011), 263–269.
Mitchell, A.J., Shiri-Feshki, M., Rate of progression of mild cognitive impairment to dementia—meta-analysis of 41 robust inception cohort studies. Acta Psychiatr. Scand. 119 (2009), 252–265, 10.1111/j.1600-0447.2008.01326.x.
Morbelli, S., Garibotto, V., Van De Giessen, E., Arbizu, J., Chételat, G., Drezgza, A., Hesse, S., Lammertsma, A.A., Law, I., Payoux, P., A Cochrane review on brain [18F] FDG PET in dementia: limitations and future perspectives. Eur. J. Nucl. Med. Mol. Imaging 42:10 (2015), 1487–1491.
Mosconi, L., Tsui, W.H., Herholz, K., Pupi, A., Drzezga, A., Lucignani, G., Reiman, E.M., Holthoff, V., Kalbe, E., Sorbi, S., Diehl-Schmid, J., Perneczky, R., Clerici, F., Caselli, R., Beuthien-Baumann, B., Kurz, A., Minoshima, S., de Leon, M.J., Multicenter standardized 18F–FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J. Nucl. Med. 49 (2008), 390–398, 10.2967/jnumed.107.045385.
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 15 (2016), 673–684.
Ossenkoppele, R., Prins, N., Pijnenburg, Y.A.L., Lemstra, A.W., van der Flier, W.M., Adriaanse, S.F., Windhorst, A.D., Handels, R.L.H., Wolfs, C.A.G., Aalten, P., Verhey, F.R.J., Verbeek, M.M., van Buchem, M.A., Hoekstra, O.S., Lammertsma, A.A., Scheltens, P., van Berckel, B.N.M., Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement. 9 (2013), 414–421, 10.1016/j.jalz.2012.07.003.
Ossenkoppele, R., Mattsson, N., Teunissen, C.E., Barkhof, F., Pijnenburg, Y., Scheltens, P., van der Flier, W.M., Rabinovici, G.D., Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. Neurobiol. Aging 36 (2015), 2340–2347.
Parnetti, L., Chiasserini, D., Eusebi, P., Giannandrea, D., Bellomo, G., De Carlo, C., Padiglioni, C., Mastrocola, S., Lisetti, V., Calabresi, P., Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. J. Alzheimers Dis. 29 (2012), 229–238.
Perani, D., FDG PET and cognitive symptoms of dementia. Clin. Transl. Imaging, 2013, 10.1007/s40336-013-0029-8.
Perani, D., FDG-PET and amyloid-PET imaging: the diverging paths. Curr. Opin. Neurol. 27 (2014), 405–413, 10.1097/WCO.0000000000000109.
Perani, D., Della Rosa, P.A., Cerami, C., Gallivanone, F., Fallanca, F., Vanoli, E.G., Panzacchi, A., Nobili, F., Pappatà, S., Marcone, A., Garibotto, V., Castiglioni, I., Magnani, G., Cappa, S.F., Gianolli, L., Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. NeuroImage Clin. 6 (2014), 445–454, 10.1016/j.nicl.2014.10.009.
Perani, D., Schillaci, O., Padovani, A., Nobili, F.M., Iaccarino, L., Della Rosa, P.A., Frisoni, G., Caltagirone, C., Erratum to “A Survey of FDG-and Amyloid-PET Imaging in Dementia and GRADE Analysis.”. Biomed. Res. Int., 2014, 2014.
Perani, D., Cerami, C., Caminiti, S.P., Santangelo, R., Coppi, E., Ferrari, L., Pinto, P., Passerini, G., Falini, A., Iannaccone, S., Cappa, S.F., Comi, G., Gianolli, L., Magnani, G., Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting. Eur. J. Nucl. Med. Mol. Imaging 43 (2016), 499–508, 10.1007/s00259-015-3170-y.
Pievani, M., Filippini, N., van den Heuvel, M.P., Cappa, S.F., Frisoni, G.B., Brain connectivity in neurodegenerative diseases—from phenotype to proteinopathy. Nat. Rev. Neurol. 10 (2014), 620–633.
Presotto, L., Ballarini, T., Caminiti, S.P., Bettinardi, V., Gianolli, L., Perani, D., Validation of 18F–FDG-PET Single-subject optimized SPM procedure with different PET scanners. Neuroinformatics 15 (2017), 151–163, 10.1007/s12021-016-9322-9.
Prestia, A., Caroli, A., Herholz, K., Reiman, E., Chen, K., Jagust, W.J., Frisoni, G.B., Group, T.O.M.C.W, Initiative, A.D.N, Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. Alzheimers Dement. 9 (2013), 677–686.
Prestia, A., Caroli, A., van der Flier, W.M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., Teunissen, C.E., Wall, A.E., Carter, S.F., Schöll, M., Choo, I.H., Nordberg, A., Scheltens, P., Frisoni, G.B., Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 80 (2013), 1048–1056, 10.1212/WNL.0b013e3182872830.
Rascovsky, K., Hodges, J.R., Knopman, D., Mendez, M.F., Kramer, J.H., Neuhaus, J., van Swieten, J.C., Seelaar, H., Dopper, E.G.P., Onyike, C.U., Hillis, A.E., Josephs, K.A., Boeve, B.F., Kertesz, A., Seeley, W.W., Rankin, K.P., Johnson, J.K., Gorno-Tempini, M.-L., Rosen, H., Prioleau-Latham, C.E., Lee, A., Kipps, C.M., Lillo, P., Piguet, O., Rohrer, J.D., Rossor, M.N., Warren, J.D., Fox, N.C., Galasko, D., Salmon, D.P., Black, S.E., Mesulam, M., Weintraub, S., Dickerson, B.C., Diehl-Schmid, J., Pasquier, F., Deramecourt, V., Lebert, F., Pijnenburg, Y., Chow, T.W., Manes, F., Grafman, J., Cappa, S.F., Freedman, M., Grossman, M., Miller, B.L., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134 (2011), 2456–2477, 10.1093/brain/awr179.
Ravaglia, G., Forti, P., Maioli, F., Martelli, M., Servadei, L., Brunetti, N., Pantieri, G., Mariani, E., Conversion of mild cognitive impairment to dementia: predictive role of mild cognitive impairment subtypes and vascular risk factors. Dement. Geriatr. Cogn. Disord. 21 (2005), 51–58.
Robb, C., Udeh-Momoh, C., Wagenpfeil, S., Schöpe, J., Alexopoulos, P., Perneczky, R., Biomarkers and functional decline in prodromal Alzheimer's disease. J. Alzheimers Dis., 2017, 1–10.
Seguin, J., Formaglio, M., Perret-Liaudet, A., Quadrio, I., Tholance, Y., Rouaud, O., Thomas-Anterion, C., Croisile, B., Mollion, H., Moreaud, O., CSF biomarkers in posterior cortical atrophy. Neurology 76 (2011), 1782–1788.
Shaffer, J.L., Petrella, J.R., Sheldon, F.C., Choudhury, K.R., Calhoun, V.D., Coleman, R.E., Doraiswamy, P.M., Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined. Radiology 266 (2013), 583–591, 10.1148/radiol.12120010/-/DC1.
Signorini, M., Paulesu, E., Friston, K., Perani, D., Colleluori, A., Lucignani, G., Grassi, F., Bettinardi, V., Frackowiak, R.S., Fazio, F., Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [18F]FDG PET: a clinical validation of statistical parametric mapping. NeuroImage 9 (1999), 63–80, 10.1006/nimg.1998.0381.
Simonsen, A.H., Herukka, S.-K., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., Engelborghs, S., Frisoni, G.B., Gabryelewicz, T., Galluzzi, S., Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimers Dement. 13 (2017), 274–284.
Sjogren, M., Vanderstichele, H., Agren, H., Zachrisson, O., Edsbagge, M., Wikkelso, C., Skoog, I., Wallin, A., Wahlund, L.-O., Marcusson, J., Nagga, K., Andreasen, N., Davidsson, P., Vanmechelen, E., Blennow, K., Tau and A{beta}42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values. Clin. Chem. 47 (2001), 1776–1781.
Smailagic, N., Vacante, M., Hyde, C., Martin, S., Ukoumunne, O., Sachpekidis, C., 18F-FDG PET for the early diagnosis of Alzheimer?s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst. Rev., 1, 2015, 10.1002/14651858.CD010632.pub2.
Stefani, A., Brusa, L., Olivola, E., Pierantozzi, M., Martorana, A., CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD. J. Neural Transm. 119 (2012), 861–875.
Storandt, M., Morris, J.C., Ascertainment bias in the clinical diagnosis of Alzheimer disease. Arch. Neurol. 67 (2010), 1364–1369.
Struyfs, H., Van Broeck, B., Timmers, M., Fransen, E., Sleegers, K., Van Broeckhoven, C., De Deyn, P.P., Streffer, J.R., Mercken, M., Engelborghs, S., Diagnostic accuracy of cerebrospinal fluid amyloid-β isoforms for early and differential dementia diagnosis. J. Alzheimers Dis. 45 (2015), 813–822.
Tang, W., Huang, Q., Wang, Y., Wang, Z.-Y., Yao, Y.-Y., Assessment of CSF Aβ 42 as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: A meta-analysis of 50 studies. J. Neurol. Sci. 345 (2014), 26–36.
Teipel, S., Drzezga, A., Grothe, M.J., Barthel, H., Chételat, G., Schuff, N., Skudlarski, P., Cavedo, E., Frisoni, G.B., Hoffmann, W., Thyrian, J.R., Fox, C., Minoshima, S., Sabri, O., Fellgiebel, A., Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection. Lancet Neurol. 14 (2015), 1037–1053, 10.1016/S1474-4422(15)00093-9.
Teune, L.K., Bartels, A.L., De Jong, B.M., Willemsen, A.T.M., Eshuis, S.a., de Vries, J.J., van Oostrom, J.C.H., Leenders, K.L., Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov. Disord. 25 (2010), 2395–2404, 10.1002/mds.23291.
Torosyan, N., Mason, K., Dahlbom, M., Silverman, D.H.S., Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline. Eur. J. Nucl. Med. Mol. Imaging 44 (2017), 1355–1363, 10.1007/s00259-017-3634-3.
Vanderstichele, H., Bibl, M., Engelborghs, S., Le Bastard, N., Lewczuk, P., Molinuevo, J.L., Parnetti, L., Perret-Liaudet, A., Shaw, L.M., Teunissen, C., Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement. 8 (2012), 65–73.
Varrone, A., Asenbaum, S., Vander Borght, T., Booij, J., Nobili, F., Någren, K., Darcourt, J., Kapucu, Ö.L., Tatsch, K., Bartenstein, P., EANM procedure guidelines for PET brain imaging using [18F] FDG, version 2. Eur. J. Nucl. Med. Mol. Imaging 36 (2009), 2103–2110.
Vos, S.J.B., Verhey, F., Frölich, L., Kornhuber, J., Wiltfang, J., Maier, W., Peters, O., Rüther, E., Nobili, F., Morbelli, S., Frisoni, G.B., Drzezga, A., Didic, M., Van Berckel, B.N.M., Simmons, A., Soininen, H., Kłoszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., Muscio, C., Herukka, S.K., Salmon, E., Bastin, C., Wallin, A., Nordlund, A., De Mendonça, A., Silva, D., Santana, I., Lemos, R., Engelborghs, S., Van Der Mussele, S., Freund-Levi, Y., Wallin, Å.K., Hampel, H., Van Der Flier, W., Scheltens, P., Visser, P.J., Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain 138 (2015), 1327–1338, 10.1093/brain/awv029.
Walhovd, K.B., Fjell, A.M., Brewer, J., McEvoy, L.K., Fennema-Notestine, C., Hagler, D.J., Jennings, R.G., Karow, D., Dale, A.M., Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. Am. J. Neuroradiol. 31 (2010), 347–354.
Warren, J.D., Fletcher, P.D., Golden, H.L., The paradox of syndromic diversity in Alzheimer disease. Nat. Rev. Neurol. 8 (2012), 451–464, 10.1038/nrneurol.2012.135.
Young, J., Modat, M., Cardoso, M.J., Mendelson, A., Cash, D., Ourselin, S., Initiative, A.D.N., Accurate multimodal probabilistic prediction of conversion to Alzheimer's disease in patients with mild cognitive impairment. NeuroImage Clin. 2 (2013), 735–745.
Yuan, Y., Gu, Z.-X., Wei, W.-S., Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. AJNR Am. J. Neuroradiol. 30 (2009), 404–410, 10.3174/ajnr.A1357.
